Marion E. Frew

2.1k total citations · 1 hit paper
5 papers, 1.5k citations indexed

About

Marion E. Frew is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Marion E. Frew has authored 5 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 3 papers in Molecular Biology and 3 papers in Genetics. Recurrent topics in Marion E. Frew's work include Acute Myeloid Leukemia Research (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers) and Acute Lymphoblastic Leukemia research (2 papers). Marion E. Frew is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers) and Acute Lymphoblastic Leukemia research (2 papers). Marion E. Frew collaborates with scholars based in United Kingdom and United States. Marion E. Frew's co-authors include David Bowen, Stephen E. Langabeer, Panagiotis Kottaridis, Rosemary E. Gale, David C. Linch, Keith Wheatley, Alan K. Burnett, G Harrison, Anthony H. Goldstone and Helen M. Walker and has published in prestigious journals such as Blood and British Journal of Haematology.

In The Last Decade

Marion E. Frew

5 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

2001 1.2k citations Panagiotis Kottaridis, Rosemary E. Gale et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marion E. Frew United Kingdom	5	1.4k	664	501	395	142	5	1.5k
Tamara Weiss Germany	9	945 0.7×	462 0.7×	456 0.9×	305 0.8×	81 0.6×	22	1.1k
Sherry R. Pierce United States	9	912 0.6×	488 0.7×	334 0.7×	219 0.6×	130 0.9×	14	1.1k
Marta Pratcorona Spain	14	791 0.6×	572 0.9×	269 0.5×	214 0.5×	68 0.5×	29	1.0k
Jessica Kohlschmidt United States	19	765 0.5×	574 0.9×	239 0.5×	198 0.5×	110 0.8×	50	1.1k
Chantal S. Goudswaard Netherlands	5	571 0.4×	414 0.6×	236 0.5×	151 0.4×	55 0.4×	7	727
J. Erika Haydu United States	8	407 0.3×	405 0.6×	289 0.6×	228 0.6×	123 0.9×	12	799
Sonja Schindela Germany	13	620 0.4×	368 0.6×	314 0.6×	158 0.4×	50 0.4×	25	830
Dean Margeson United States	5	711 0.5×	552 0.8×	289 0.6×	167 0.4×	84 0.6×	9	951
Mauro Nanni Italy	16	456 0.3×	402 0.6×	294 0.6×	112 0.3×	86 0.6×	43	804
Heinz-A. Horst Germany	6	443 0.3×	360 0.5×	253 0.5×	135 0.3×	163 1.1×	6	791

Countries citing papers authored by Marion E. Frew

Since Specialization

Citations

This map shows the geographic impact of Marion E. Frew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marion E. Frew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marion E. Frew more than expected).

Fields of papers citing papers by Marion E. Frew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marion E. Frew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marion E. Frew. The network helps show where Marion E. Frew may publish in the future.

Co-authorship network of co-authors of Marion E. Frew

This figure shows the co-authorship network connecting the top 25 collaborators of Marion E. Frew. A scholar is included among the top collaborators of Marion E. Frew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marion E. Frew. Marion E. Frew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Johan, Muhammad Farid, David Bowen, Marion E. Frew, Anne Goodeve, & John T. Reilly. (2005). Aberrant methylation of the negative regulators RASSFIA, SHP‐1 and SOCS‐1 in myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology. 129(1). 60–65. 67 indexed citations

2.

Bowen, David, Marion E. Frew, Sara Rollinson, et al.. (2003). CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated withFLT3 internal tandem duplication. Blood. 101(7). 2770–2774. 31 indexed citations

3.

Kottaridis, Panagiotis, Rosemary E. Gale, Stephen E. Langabeer, et al.. (2002). Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 100(7). 2393–2398. 239 indexed citations

4.

Kottaridis, Panagiotis, Rosemary E. Gale, Marion E. Frew, et al.. (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 98(6). 1752–1759. 1178 indexed citations breakdown →

5.

Kottaridis, Panagiotis, Marion E. Frew, G Harrison, et al.. (2000). The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials.. Blood. 96. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact